Elizabeth A. Griffiths

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Clinical Sciences, Oncology +8

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Jan Krönke, Emma C. Fink, Paul W. Hollenbach et al. · Nature · 2015 · 836 citations · Full text

Medicine, Molecular Biology, Oncology +8

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali et al. · Journal of the National Comprehensive Cancer Network · 2016 · 296 citations

Medicine, Hematology, Oncology +17

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Jean‐Pierre J. Issa, Gail J. Roboz, David A. Rizzieri et al. · The Lancet Oncology · 2015 · 281 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia‐Manero, Elizabeth A. Griffiths, David P. Steensma et al. · Blood · 2020 · 210 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10